The test’s rigorous protocol includes washing, isolating, and counting peripheral blood mononuclear cells. Credit: SOMKID THONGDEE/Shutterstock.com.

Revvity, a global provider of health science solutions, has announced the launch of the automated tuberculosis testing platform, Auto-Pure 2400 liquid handler, for use with the T-SPOT.TB test.

The integration of Revvity’s T-SPOT.TB test with the Auto-Pure 2400 liquid handling platform from Allsheng marks a significant advancement in the field of tuberculosis testing.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

This new automated tuberculosis testing platform is designed for ease of use and provides efficient workflows in the lab. It also enhances productivity by reducing hands-on time for technicians.

The platform’s intuitive software interface further simplifies the workflow.

Equipped with magnetic cell isolation technology, the Auto-Pure 2400 system is tailored for processing up to 24 samples per run.

See Also:

It can complete the day-one workflow of the T-SPOT.TB test in less than three and a half hours, requiring only one mid-run interaction from the user.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The T-SPOT.TB test is developed for detecting latent tuberculosis infection (LTBI). It is an interferon-gamma release assay (IGRA) based on the enzyme-linked immunospot technology.

The test’s rigorous protocol includes washing, isolating, and counting peripheral blood mononuclear cells (PBMCs) before the test.

Revvity infectious diseases general manager Darren Sher said: “The ability to use the Auto-Pure 2400 platform with our T-SPOT.TB test provides labs with an efficient workflow, allowing latent TB testing to be run in a mid-high-volume setting, without having to compromise on the clinical performance of the test.

“With this solution, more labs can offer clinicians access to the most accurate TB diagnostic on the market.”

Last month, Revvity unveiled a new ‘sample-to-answer’ workflow designed to accelerate newborn sequencing research.

This research-use-only, flexible end-to-end workflow solution is intended to allow users to utilise different reagents, instruments, and databases based on the needs of a laboratory.